EU and US could reach trade deal this weekend - Reuters
James C. Borel, a director at Neogen Corp (NASDAQ:NEOG), recently acquired 35,000 shares of the company’s common stock. The purchase, dated April 24, 2025, was executed at a price of approximately $4.894 per share, totaling around $171,290. Following this transaction, Borel’s direct ownership in Neogen Corp increased to 60,474 shares.The timing of this insider purchase appears notable, as InvestingPro data shows the stock has experienced a significant 12% return over the past week, though it remains down about 64% over the past six months. With a market capitalization of $1.14 billion and analysts projecting profitability this year, this insider buying could signal confidence in the company’s prospects.For deeper insights into NEOG’s valuation and growth potential, InvestingPro subscribers have access to 13 additional ProTips and a comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.
In other recent news, Neogen Corporation reported its fiscal Q3 2025 earnings, revealing a surprising increase in earnings per share (EPS) to $0.10, exceeding the forecast of -$0.01. However, the company’s revenue of $221 million fell short of the expected $232.36 million. Neogen also announced the sale of its cleaners and disinfectants division to Kersia Group for $130 million, with the transaction expected to close in the first quarter of Neogen’s 2026 fiscal year. This sale is anticipated to improve Neogen’s profit margins and reduce its net leverage ratio. Guggenheim analysts adjusted their outlook on Neogen by lowering the price target to $13.00 from $15.00 but maintained a Buy rating, citing a mixed performance with positive developments and ongoing challenges. The company has revised its revenue and EBITDA guidance downward, reflecting struggles in financial growth amid a softer macroeconomic environment. Neogen’s Petrifilm product line is set to begin production in the upcoming fall, and the company continues to focus on restructuring its genomics business. Despite these challenges, Guggenheim analysts remain confident in Neogen’s long-term potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.